Hepatitis B in immunosuppressed cancer patients: Pathogenesis, incidence and prophylaxis

Critical Reviews in Oncology/Hematology

Volumn 87, Issue 1, 2013, Pages 12-27

  Mandalà, Mario ^a   Fagiuoli, Stefano ^a   Francisci, Daniela ^b   Bruno, Raffaele ^c   Merelli, Barbara ^a   Pasulo, Luisa ^a   Tondini, Carlo ^a   Labianca, Roberto ^a   Roila, Fausto ^d  

^a PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^b SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

^d S MARIA HOSPITAL   (Italy)

Author keywords

Cancer; Hepatitis B; Pathogenesis; Prophylaxis; Therapy

Indexed keywords

ADEFOVIR DIPIVOXIL; ANTIVIRUS AGENT; BLEOMYCIN; CARBOPLATIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ENTECAVIR; ETOPOSIDE; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; IFOSFAMIDE; INFLIXIMAB; LAMIVUDINE; METHOTREXATE; NUCLEOSIDE ANALOG; PREDNISOLONE; PREDNISONE; PROCARBAZINE; RITUXIMAB; TELBIVUDINE; TENOFOVIR; VINBLASTINE; VINCRISTINE;

ANTIVIRAL THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMOPROPHYLAXIS; DRUG POTENCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION RISK; LIVER INJURY; LYMPHOMA; PATHOGENESIS; PATIENT MONITORING; PRACTICE GUIDELINE; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; REVIEW; SCREENING; SIDE EFFECT; VIRUS CARRIER; VIRUS REACTIVATION;

HEPATITIS B; HEPATITIS B VIRUS; HUMANS; IMMUNOCOMPROMISED HOST; INCIDENCE; NEOPLASMS; PREMEDICATION; RISK FACTORS; VIRUS ACTIVATION;

EID: 84878557601     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2012.12.004     Document Type: Review

References (105)

1. Ganem D., Prince A.M. Hepatitis B virus infection - natural history and clinical consequences. New England Journal of Medicine 2004, 350:1118-1129.
2. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. Journal of Viral Hepatitis 2004, 11:97-107.
3. Hoofnagle J.H., Doo E., Liang T.J., Fleischer R., Lok A.S. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007, 45:1056-1075.
4. Liaw Y.F., Chu C.M. Hepatitis B virus infection. Lancet 2009, 373:582-592.
5. Yeo W., Johnson P.J. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006, 43:209-220.
6. Galbraith R.M., Eddleston A.L., Williams R., Zuckerman A.J. Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet 1975, 2:528-530.
7. Marzano A., Angelucci E., Andreone P., et al. Italian Association for the Study of the Liver. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Digestive and Liver Disease 2007, 39:397-408.
8. Bird G.L., Smith H., Portmann B., Alexander G.J., Williams R. Acute liver decompensation on withdrawal of cytotoxic chemotherapy and immunosuppressive therapy in hepatitis B carriers. Quarterly Journal of Medicine 1989, 73:895-902.
9. Lok A.S., Liang R.H., Chiu E.K., et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991, 100:182-188.
10. Soh L.T., Ang P.T., Sng I., Chua E.J., Ong Y.W. Fulminant hepatic failure in non-Hodgkin lymphoma patients treated with chemotherapy. European Journal of Cancer 1992, 28:1338-1339.
11. Yeo W., Chan P.K., Hui P., et al. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. Journal of Medical Virology 2003, 70:553-561.
12. Lau G.K., Leung Y.H., Fong D.Y., et al. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood 2002, 99:2324-2330.
13. Francisci D., Falcinelli F., Schiaroli E., et al. Reactivation of hepatitis B virus replication due to cytotoxic therapy: a five-year prospective study. Tumori 2012, 98:220-224.
14. Nakamura Y., Motokura T., Fujita A., Yamashita T., Ogata E. Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987-1991. Cancer 1996, 78:2210-2215.
15. Kohrt H.E., Ouyang D.L., Keeffe E.B. Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Alimentary Pharmacology and Therapeutics 2006, 24:1003-1016.
16. Ries L.A., Melbert D., Krapcho M., et al. SEER Cancer Statistics Review, 1975-2003 2005, National Cancer Institute, Bethesda, MD.
17. Alter M.J. Epidemiology of hepatitis B in Europe and worldwide. Journal of Hepatology 2003, 39:64-69.
18. Coiffier B., Lepage E., Briere J., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine 2002, 346:235-242.
19. Feugier P., Van Hoof A., Sebban C., et al. Long- term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. Journal of Clinical Oncology 2005, 23:4117-4126.
20. Pfreundschuh M., Trümper L., Osterborg A., et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncology 2006, 7:379-391.
21. Yeo W., Chan T.C., Leung N.W.Y., et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. Journal of Clinical Oncology 2009, 27:605-611.
22. Van der Kolk L.E., Baars J.W., Prins M.H., van Oers M.H. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 2002, 100:2257-2259.
23. Osterborg A., Dyer M.J., Bunjes D., et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia: European Study Group of CAMPATH-1H treatment in chronic lymphocytic leukemia. Journal of Clinical Oncology 1997, 15:1567-1574.
24. Lazdina U., Alheim M., Nyström J., et al. Priming of cytotoxic T cell responses to exogenous hepatitis B virus core antigen is B cell dependent. Journal of General Virology 2003, 84:139-146.
25. Aksoy S., Harputluoglu H., Kilickap S., et al. Rituximab-related viral infections in lymphoma patients. Leukemia and Lymphoma 2007, 48:1307-1312.
26. Stasi R., Del Poeta G., Stipa E., et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 2007, 110:2924-2930.
27. Tsutsumi Y., Tanaka J., Kawamura T., et al. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma. Annals of Hematology 2004, 83:58-60.
28. Tur-Kaspa R., Shaul Y., Moore D.D., et al. The glucocorticoid receptor recognizes a specific nucleotide sequence in hepatitis B virus DNA causing increased activity of the HBV enhancer. Virology 1988, 167:630-633.
29. Matsue K., Kimura S., Takanashi Y., et al. Reactivation of hepatitis B virus after rituximab containing treatment in patients with CD20-positive B-cell lymphoma. Cancer 2010, 116:4769-4776.
30. Cheng A.L., Hsiung C.A., Su I.J., et al. Hepatitis B virus reactivation in lymphoma steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 2003, 37:1320-1328.
31. Kim M.K., Ahn J.H., Kim S.B., et al. Hepatitis B reactivation during adjuvant anthracycline-based chemotherapy in patients with breast cancer: a single institution's experience. Korean Journal of Internal Medicine 2007, 22:237-243.
32. Zhong S., Yeo W., Schroder C., et al. High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy. Journal of Viral Hepatitis 2004, 11:55-59.
33. Alexopoulos C.G., Vaslamatzis M., Hatzidimitriou G. Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours. British Journal of Cancer 1999, 81:69-74.
34. Yeo W., Chan P.K.S., Zhong S., et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. Journal of Medical Virology 2000, 62:299-307.
35. Jang J.W., Choi J.Y., Bae S.H., et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology 2006, 43:233-240.
36. Kusumoto S., Tanaka Y., Ueda R., Mizokami M. Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy. Journal of Gastroenterology 2011, 46:9-16.
37. Lau G.K., Yiu H.H., Fong D.Y., et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003, 125:1742-1749.
38. Pei S.N., Chen C.H., Lee C.M., et al. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Annals of Hematology 2009, 89:255-262.
39. Hui C.K., Cheung W.W., Zhang H.Y., Au W.Y., Yueng Y.H., Leung A.Y. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006, 131:59-68.
40. Pérez-Alvarez R., Díaz-Lagares C., García-Hernández F., et al. BIOGEAS Study Group. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine 2011, 90:359-371.
41. Moses S.E., Lim Z.Y., Sudhanva M., et al. Lamivudine prophylaxis and treatment of hepatitis B virus-exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab. Journal of Medical Virology 2006, 78:1560-1563.
42. Esteve M., Saro C., González-Huix F., et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004, 53:1363-1365.
43. Kumagai K., Takagi T., Nakamura S., et al. Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Annals of Oncology 1997, 8:107-109.
44. Hoofnagle J.H., Dusheiko G.M., Schafer D.F., et al. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Annals of Internal Medicine 1982, 96:447-449.
45. Hui C.K., Lie A., Au W.Y., et al. A long-term follow-up study on hepatitis B surface antigen-positive patients undergoing allogeneic hematopoietic stem cell transplantation. Blood 2005, 106:464-469.
46. Pungpapong S., Kim W.R., Poterucha J.J. Natural history of hepatitis B virus infection: an update for clinicians. Mayo Clinic Proceedings 2007, 82:967-975.
47. Fukushima N., Mizuta T., Tanaka M., et al. Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier. Annals of Oncology 2009, 20:2013-2017.
48. Raimondo G., Pollicino T., Cacciola I., Squadrito G. Occult hepatitis B virus infection. Journal of Hepatology 2007, 46:160-170.
49. Urbani S., Fagnoni F., Missale G., Franchini M. The role of anti-core antibody response in the detection of occult hepatitis B virus infection. Clinical Chemistry and Laboratory Medicine 2010, 48:23-29.
50. Siagris D., Christofidou M., Triga K., et al. Occult hepatitis B virus infection in hemodialysis patients with chronic HCV infection. Journal of Nephrology 2006, 19:327-333.
51. Kanbay M., Gur G., Akcay A., et al. Is hepatitis C virus positivity a contributing factor to occult hepatitis B virus infection in hemodialysis patients?. Digestive Diseases and Sciences 2006, 51:1962-1966.
52. Sayan M., Dogan C. Genotype/subgenotype distribution of hepatitis B virus among hemodialysis patients with chronical hepatitis B. Annals of Hepatology 2012, 11:849-854.
53. Nunez M., Rios P., Perez-Olmeda M., Soriano V. Lack of 'occult' hepatitis B virus infection in HIV-infected patients. AIDS 2002, 16:2099-2101.
54. Minuk G.Y., Sun D.F., Uhanova J., et al. Occult hepatitis B virus infection in a North American community-based population. Journal of Hepatology 2005, 42:480-485.
55. Kim S.M., Lee K.S., Park C.J., et al. Prevalence of occult HBV infection among subjects with normal serum ALT levels in Korea. Journal of Infection 2007, 54:185-191.
56. Hui C.K., Sun J., Au W.Y., et al. Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area. Journal of Hepatology 2005, 42:813-819.
57. Koo Y.X., Tay M., Teh Y.E., et al. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis. Annals of Hematology 2011, 90:1219-1223.
58. Viganò M., Vener C., Lampertico P., et al. Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT. Bone Marrow Transplantation 2011, 46:125-131.
59. Tur-Kaspa R., Burk R.D., Shaul Y., Shafritz D.A. Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proceedings of the National Academy of Sciences of the United States of America 1986, 83:1627-1631.
60. Weinbaum C.M., Williams I., Mast E.E., et al. Centers for Disease Control and Prevention. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR: Recommendations and Reports 2008, 57:1-20.
61. Lok A.S., McMahon B.J. Chronic hepatitis B: update 2009. Hepatology 2009, 50:661-662.
62. Artz A.S., Somerfield M.R., Feld J.J., et al. American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. Journal of Clinical Oncology 2010, 28:3199-3202.
63. Barclay S., Pol S., Mutimer D., et al. The management of chronic hepatitis B in the immunocompromised patient: recommendations from a single topic meeting. Journal of Clinical Virology 2008, 42:104-115.
64. European Association for the Study of the Liver EASL Clinical Practice Guidelines: management of chronic hepatitis B. Journal of Hepatology 2009, 50:227-242.
65. Niitsu N., Hagiwara Y., Tanae K., Kohri M., Takahashi N. Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy. Journal of Clinical Oncology 2010, 28:5097-5100.
66. Tran T.T., Rakoski M.O., Martin P., Poordad F. Screening for hepatitis B in chemotherapy patients: survey of current oncology practices. Alimentary Pharmacology and Therapeutics 2010, 31:240-246.
67. Day F.L., Karnon J., Rischin D. Cost-effectiveness of universal hepatitis B virus screening in patients beginning chemotherapy for solid tumors. Journal of Clinical Oncology 2011, 29:3270-3277.
68. Zurawska U., Hicks L.K., Woo G., et al. Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis. Journal of Clinical Oncology 2012, 30:3167-3173.
69. Loomba R., Rowley A., Wesley R., et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Annals of Internal Medicine 2008, 148:519-528.
70. Chang T.T., Gish R.G., de Man R., et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. New England Journal of Medicine 2006, 354:1001-1010.
71. Perez-Roldan F., Gonzalez-Carro P., Villafanez-Garcia M.C. Adefovir dipivoxil for chemotherapy-induced activation of hepatitis B virus infection. New England Journal of Medicine 2005, 352:310-311.
72. Lai C.L., Shouval D., Lok A.S., et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. New England Journal of Medicine 2006, 354:1011-1020.
73. Zhao S.S., Tang L., Fan X., Chen L., Zhou R., Dai X. Comparison of the efficacy of lamivudine and telbivudine in the treatment of chronic hepatitis B: a systematic review. Virology Journal 2010, 7:11-18.
74. Zhao S.S., Tang L.H., Dai X.H., et al. Comparison of the efficacy of tenofovir and adefovir in the treatment of chronic hepatitis B: a systematic review. Virology Journal 2011, 8:111-118.
75. Dai M.S., Chao T.Y. Lamivudine therapy in HBsAg-carrying breast cancer patients undergoing chemotherapy: prophylactic or preemptive?. Breast Cancer Research and Treatment 2005, 92:95-96.
76. Yeo W., Ho W.M., Hui P., et al. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. Breast Cancer Research and Treatment 2004, 88:209-215.
77. Long M., Jia W., Li S., et al. A single-center, prospective and randomized controlled study: can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy?. Breast Cancer Research and Treatment 2011, 127:705-712.
78. Loomba R., Liang T.J. Novel approaches to new therapies for hepatitis B virus infection. Antiviral Therapy 2006, 11:1-15.
79. Hui C.K., Lie A., Au W.Y., et al. Effectiveness of prophylactic Anti-HBV therapy in allogeneic hematopoietic stem cell transplantation with HBsAg positive donors. American Journal of Transplantation 2005, 5:1437-1445.
80. Giaccone L., Festuccia M., Marengo A., et al. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation. Biology of Blood and Marrow Transplantation 2010, 16:809-817.
81. Ceneli O., Ozkurt Z.N., Acar K., et al. Hepatitis B-related events in autologous hematopoietic stem cell transplantation recipients. World Journal of Gastroenterology 2010, 16:1765-1771.
82. Borentain P., Colson P., Coso D., et al. Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer. Journal of Viral Hepatitis 2010, 17:807-815.
83. Hammond S.P., Borchelt A.M., Ukomadu C., Ho V.T., Baden L.R., Marty F.M. Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation 2009, 15:1049-1059.
84. Ji D., Cao J., Hong X., et al. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/HBcAb-positive: a multicenter retrospective study. European Journal of Haematology 2010, 85:243-250.
85. Weinbaum C.M., Williams I., Mast E.E., et al. Centers for Disease Control and Prevention. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR: Recommendations and Reports 2008, 57(RR-8):1-20.
86. Sorrell M.F., Belongia E.A., Costa J., et al. National Institutes of Health consensus development conference statement: management of hepatitis B. Hepatology 2009, 49(5 Suppl.):S4-S12.
87. APASL Guidelines for HBV Management. Hepatology International 2008, 2:263-283.
88. Morotta P., Lucas K. Management of hepatitis B: a longitudinal national survey - impact of the Canadian Hepatitis B Consensus Guidelines. Canadian Journal of Gastroenterology 2010, 24(9):537-542.
89. Yeo W., Hui E.P., Chan A.T., et al. Prevention of hepatitis B virus reactivation in patients with nasopharyngeal carcinoma with lamivudine. American Journal of Clinical Oncology 2005, 28:379-384.
90. Dai M.S., Wu P.F., Shyu R.Y., Lu J.J., Chao T.Y. Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration. Liver International 2004, 24:540-546.
91. Dai M.S., Wu P.F., Lu J.J., Shyu R.Y., Chao T.Y. Preemptive use of lamivudine in breast cancer patients carrying hepatitis B virus undergoing cytotoxic chemotherapy: a longitudinal study. Supportive Care in Cancer 2004, 12:191-196.
92. Yun J., Kim K.H., Kang E.S., et al. Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy. British Journal of Cancer 2011, 104:559-563.
93. Sohn B.S., Ahn J.H., Jung K.H., et al. Updated longitudinal data on acute exacerbation of chronic hepatitis B in patients with breast cancer receiving anthracycline-based adjuvant chemotherapy: therapeutic vs. pre-emptive use of lamivudine. Japanese Journal of Clinical Oncology 2011, 41:59-66.
94. Nagamatsu H., Itano S., Nagaoka S., et al. Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy. American Journal of Gastroenterology 2004, 99:2369-2375.
95. Hsu C., Hsiung C.A., Su I.J., et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology 2008, 47:844-853.
96. Idilman R., Arat M., Soydan E., et al. Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies. Journal of Viral Hepatitis 2004, 11:141-147.
97. Shibolet O., Ilan Y., Gillis S., Hubert A., Shouval D., Safadi R. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood 2002, 100:391-396.
98. Leaw S.J., Yen C.J., Huang W.T., Chen T.Y., Su W.C., Tsao C.J. Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. Annals of Hematology 2004, 83:270-275.
99. Lee G.W., Ryu M.H., Lee J.L., et al. The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBs Ag)-positive patients with non-Hodgkin's lymphoma who receive cytotoxic chemotherapy. Journal of Korean Medical Science 2003, 18:849-854.
100. Li Y.H., He Y.F., Jiang W.Q., et al. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer 2006, 106:1320-1325.
101. Persico M., De Marino F., Russo G.D., et al. Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma. Blood 2002, 99:724-725.
102. Chen X.Q., Peng J.W., Lin G.N., Li M., Xia Z.J. The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg-positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy. Medical Oncology 2012, 29:1237-1241.
103. Li H.R., Huang J.J., Guo H.Q., Li M., Xia Z.J. Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy. Journal of Viral Hepatitis 2011, 18:877-883.
104. Tsutsumi Y., Shigematsu A., Hashino S., et al. Analysis of reactivation of hepatitis B virus in the treatment of B cell non-Hodgkin's lymphoma in Hokkaido. Annals of Hematology 2009, 88:375-377.
105. Kim J.S., Hahn J.S., Park S.Y., et al. Long-term outcome after prophylactic lamivudine treatment on hepatitis B virus reactivation in non-Hodgkin's lymphoma. Yonsei Medical Journal 2007, 48:78-89.